Browse TRIM71

Summary
SymbolTRIM71
Nametripartite motif containing 71, E3 ubiquitin protein ligase
Aliases LIN41; LIN-41; tripartite motif-containing 71; tripartite motif containing 71; abnormal cell LINeage LIN-41; ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, P-body
Domain PF00630 Filamin/ABP280 repeat
PF01436 NHL repeat
PF00643 B-box zinc finger
Function

E3 ubiquitin-protein ligase that cooperates with the microRNAs (miRNAs) machinery and promotes embryonic stem cells proliferation and maintenance (Probable). Binds to miRNAs and associates with AGO2, participating in post-transcriptional repression of transcripts such as CDKN1A (By similarity). In addition, participates in post-transcriptional mRNA repression in a miRNA independent mechanism (PubMed:23125361). Facilitates the G1-S transition to promote rapid embryonic stem cell self-renewal by repressing CDKN1A expression. Required to maintain proliferation and prevent premature differentiation of neural progenitor cells during early neural development: positively regulates FGF signaling by controlling the stability of SHCBP1 (By similarity). Specific regulator of miRNA biogenesis. Binds to miRNA MIR29A hairpin and postranscriptionally modulates MIR29A levels, which indirectly regulates TET proteins expression (PubMed:28431233).

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0001838 embryonic epithelial tube formation
GO:0001841 neural tube formation
GO:0001843 neural tube closure
GO:0006417 regulation of translation
GO:0008543 fibroblast growth factor receptor signaling pathway
GO:0010586 miRNA metabolic process
GO:0010608 posttranscriptional regulation of gene expression
GO:0014020 primary neural tube formation
GO:0016331 morphogenesis of embryonic epithelium
GO:0016441 posttranscriptional gene silencing
GO:0016458 gene silencing
GO:0017148 negative regulation of translation
GO:0021915 neural tube development
GO:0031047 gene silencing by RNA
GO:0034248 regulation of cellular amide metabolic process
GO:0034249 negative regulation of cellular amide metabolic process
GO:0035148 tube formation
GO:0035194 posttranscriptional gene silencing by RNA
GO:0035195 gene silencing by miRNA
GO:0035239 tube morphogenesis
GO:0035278 miRNA mediated inhibition of translation
GO:0040029 regulation of gene expression, epigenetic
GO:0040033 negative regulation of translation, ncRNA-mediated
GO:0043487 regulation of RNA stability
GO:0043488 regulation of mRNA stability
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045974 regulation of translation, ncRNA-mediated
GO:0050779 RNA destabilization
GO:0051865 protein autoubiquitination
GO:0060147 regulation of posttranscriptional gene silencing
GO:0060148 positive regulation of posttranscriptional gene silencing
GO:0060562 epithelial tube morphogenesis
GO:0060606 tube closure
GO:0060964 regulation of gene silencing by miRNA
GO:0060966 regulation of gene silencing by RNA
GO:0060968 regulation of gene silencing
GO:0061157 mRNA destabilization
GO:0061158 3'-UTR-mediated mRNA destabilization
GO:0061351 neural precursor cell proliferation
GO:0071774 response to fibroblast growth factor
GO:0072089 stem cell proliferation
GO:0072175 epithelial tube formation
GO:2000177 regulation of neural precursor cell proliferation
GO:2000637 positive regulation of gene silencing by miRNA
Molecular Function GO:0004842 ubiquitin-protein transferase activity
GO:0016874 ligase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0030371 translation repressor activity
GO:0035198 miRNA binding
GO:0045182 translation regulator activity
GO:0061630 ubiquitin protein ligase activity
GO:0061659 ubiquitin-like protein ligase activity
Cellular Component GO:0000932 cytoplasmic mRNA processing body
GO:0035770 ribonucleoprotein granule
GO:0036464 cytoplasmic ribonucleoprotein granule
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983168: Antigen processing
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-168256: Immune System
Summary
SymbolTRIM71
Nametripartite motif containing 71, E3 ubiquitin protein ligase
Aliases LIN41; LIN-41; tripartite motif-containing 71; tripartite motif containing 71; abnormal cell LINeage LIN-41; ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TRIM71 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTRIM71
Nametripartite motif containing 71, E3 ubiquitin protein ligase
Aliases LIN41; LIN-41; tripartite motif-containing 71; tripartite motif containing 71; abnormal cell LINeage LIN-41; ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TRIM71 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTRIM71
Nametripartite motif containing 71, E3 ubiquitin protein ligase
Aliases LIN41; LIN-41; tripartite motif-containing 71; tripartite motif containing 71; abnormal cell LINeage LIN-41; ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TRIM71 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0540.793
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0020.997
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1040.765
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8690.0898
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.0390.367
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.650.616
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.5850.522
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.6720.658
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2830.876
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0490.905
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.130.822
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.9020.00181
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TRIM71 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.46.80.61
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTRIM71
Nametripartite motif containing 71, E3 ubiquitin protein ligase
Aliases LIN41; LIN-41; tripartite motif-containing 71; tripartite motif containing 71; abnormal cell LINeage LIN-41; ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TRIM71. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTRIM71
Nametripartite motif containing 71, E3 ubiquitin protein ligase
Aliases LIN41; LIN-41; tripartite motif-containing 71; tripartite motif containing 71; abnormal cell LINeage LIN-41; ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TRIM71. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TRIM71.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTRIM71
Nametripartite motif containing 71, E3 ubiquitin protein ligase
Aliases LIN41; LIN-41; tripartite motif-containing 71; tripartite motif containing 71; abnormal cell LINeage LIN-41; ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TRIM71. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTRIM71
Nametripartite motif containing 71, E3 ubiquitin protein ligase
Aliases LIN41; LIN-41; tripartite motif-containing 71; tripartite motif containing 71; abnormal cell LINeage LIN-41; ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TRIM71 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTRIM71
Nametripartite motif containing 71, E3 ubiquitin protein ligase
Aliases LIN41; LIN-41; tripartite motif-containing 71; tripartite motif containing 71; abnormal cell LINeage LIN-41; ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TRIM71 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTRIM71
Nametripartite motif containing 71, E3 ubiquitin protein ligase
Aliases LIN41; LIN-41; tripartite motif-containing 71; tripartite motif containing 71; abnormal cell LINeage LIN-41; ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TRIM71 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.